Adil Abid Nawaz Khan, Rehman Bakht, Raza Syed S, Khan Muhammad A
Internal Medicine, Community Medical Center, Fresno, USA.
Internal Medicine, Khyber Medical College/Teaching Hospital, Peshawar, PAK.
Cureus. 2025 Mar 20;17(3):e80927. doi: 10.7759/cureus.80927. eCollection 2025 Mar.
Histiocytic sarcoma (HS) is a rare and aggressive hematological malignancy. It is derived from the lineage of macrophages or monocytes. HS commonly presents as a mass in areas such as the gastrointestinal tract and soft tissues. This case highlights the clinical challenges in diagnosing and managing HS in a 37-year-old female patient. Accurate diagnosis relies on immunohistochemistry and molecular studies, while treatment outcomes remain suboptimal. The patient underwent multimodal therapies, including chemotherapy, targeted therapy, and radiation therapy, with disease progression observed despite treatment. This report underscores the need for novel approaches to improve outcomes in HS and the role of ARID2 mutations, which in our case limits the applicability of immune checkpoint inhibitors in disease management.
组织细胞肉瘤(HS)是一种罕见且侵袭性强的血液系统恶性肿瘤。它起源于巨噬细胞或单核细胞谱系。HS通常表现为胃肠道和软组织等部位的肿块。本病例突出了一名37岁女性患者诊断和治疗HS时面临的临床挑战。准确诊断依赖于免疫组织化学和分子研究,而治疗效果仍不尽人意。该患者接受了多模式治疗,包括化疗、靶向治疗和放射治疗,尽管进行了治疗,但仍观察到疾病进展。本报告强调需要新的方法来改善HS的治疗效果,以及ARID2突变的作用,在我们的病例中,这限制了免疫检查点抑制剂在疾病管理中的适用性。